Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease

Inclusion Criteria: Inclusion Criteria PDD * Male or female ≥ 60 years old; * Diagnose of PD probable or definite according to criteria of the United Kingdom Parkinson's Disease Society Brain Bank; * The Hoehn \& Yahr stage of the disease between 3 and 5 in off state; * Diagnose of dementia established according to the fourth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and the diagnostic guidelines for dementia of the Movement Disorders Society (MDS); * The score of the Mini-Mental State Examination of Folstein (MMSE) \<24; * The score on the Mattis Dementia Rating Scale (MDRS) \<136. Inclusion criteria PDND: * Male or female ≥ 60 years old; * Diagnose of PD probable or definite according to criteria of the United Kingdom Parkinson's Disease Society Brain Bank; * The Hoehn \& Yahr stage of the disease between 3 and 5 in OFF state; * The score of the Mini-Mental State Examination of Folstein (MMSE) ≥24; * The score on the Mattis Dementia Rating Scale (MDRS) ≥136. Inclusion criteria Controls: * Male or female ≥ 60 years old; * No known diagnosis of neuropsychiatric diseases * The score of the Mini-Mental State Examination of Folstein (MMSE) ≥24; * The score on the Mattis Dementia Rating Scale (MDRS) ≥136. Exclusion Criteria: * The subject is pregnant or breastfeeding; * The subject has a history of drug abuse or alcohol; * The subject has developed dementia in the first year of parkinsonism or before than parkinsonism; * The subject meets criteria for vascular dementia; * The subject has symptoms suggestive of other types of parkinsonism (multi-system atrophy cortico-basal, supra-nuclear palsy progressive degeneration) or degenerative dementia (fronto-temporal dementia); * The subject has a moderate or severe renal functional impairment (serum creatinine\> 1.5 mg / dL); * The subject has a moderate or severe hepatic impairment (bilirubin\> 2 times the upper limit of normal, transaminases\> 3 times the upper limit of normal); * The subject presents structural abnormalities in basal ganglia or cortical level on magnetic resonance imaging or computerized tomography; * The subject has participated in a clinical study with an investigational drug product within 30 days prior to screening and / or radiopharmaceutical in a minimum period of 5 radioactive half-lives prior to screening; * Occupational exposure to radiation\> 15 milliSievert (mSv) / year * The subject has received treatment with non-steroidal anti-inflammatory drugs during the 30-day period before the PET scan * The subject has allergy to the investigational product or any of its components; * The subject has a clinically active, serious disease with a reduced life expectancy; * The subject is claustrophobic / a. * The subject has received in the last 364 days a dose of ionizing radiation that coupled with the study dose exceeds 10 mSv